Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: term safetylong termthe longand efficacycriteria subject
  Phrases that lowered it: japanesepressuresafety ofefficacysitting
• Sponsor's past termination rate: 14.9% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 400 (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Sponsor's past trials: 840 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 80% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 80 (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 16 (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 4 (raises risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients NCT01204853 · started 2010 · scored riskier than 23% of active trials terminated
• Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety NCT00796510 · started 2010 · scored riskier than 47% of active trials terminated
• Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil NCT00796666 · started 2009 · scored riskier than 55% of active trials terminated
• Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS) NCT00795639 · started 2008 · scored riskier than 92% of active trials terminated
• A Study to Evaluate GSK1325760A - a Long-Term Extension Study NCT00554619 · started 2008 · scored riskier than 46% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.